Table 1 Baseline characteristics before and after propensity score matching.
Variables | Before matching | After matching | ||||
|---|---|---|---|---|---|---|
Rituximab (n = 245) | Control (n = 1054) | P | Rituximab (n = 239) | Control (n = 401) | P | |
Age (years) | 46.1 ± 10.5 | 45.1 ± 11.5 | 0.210 | 46.0 ± 10.6 | 44.6 ± 12.2 | 0.144 |
Sex, males | 116 (47.3%) | 645 (61.2%) | <0.001 | 115 (48.1%) | 207 (51.6%) | 0.391 |
Body mass index (kg/m2) | 22.3 ± 3.4 | 22.5 ± 3.3 | 0.298 | 22.3 ± 3.4 | 22.3 ± 3.5 | 0.754 |
Deceased donor | 20 (8.2%) | 334 (31.7%) | <0.001 | 20 (8.4%) | 40 (10.0%) | 0.500 |
Dialysis duration (months) | 4 (27) | 13 (73) | <0.001 | 4 (28) | 5 (28) | 0.429 |
Retransplantation | 39 (15.9%) | 87 (8.3%) | <0.001 | 33 (13.8%) | 38 (9.5%) | 0.091 |
Use of tacrolimus (vs. cyclosporin) | 237 (96.7%) | 776 (73.6%) | <0.001 | 231 (96.7%) | 384 (95.8%) | 0.573 |
Pretrasnplant alcohol use | 47 (19.2%) | 184 (17.5%) | 0.524 | 47 (19.7%) | 61 (15.2%) | 0.146 |
Pretransplant smoking | 47 (19.2%) | 215 (20.4%) | 0.669 | 47 (19.7%) | 77 (19.2%) | 0.886 |
Pretransplant DM | 71 (29.0%) | 193 (18.3%) | <0.001 | 66 (27.6%) | 105 (26.2%) | 0.692 |
Pretransplant ASCVD history | 19 (7.8%) | 71 (6.7%) | 0.572 | 18 (7.5%) | 31 (7.7%) | 0.927 |
SBP ≥ 140 mm Hg | 111 (50.9%) | 568 (57.5%) | 0.074 | 109 (51.4%) | 214 (56.3%) | 0.251 |
DBP ≥ 90 mm Hg | 84 (38.7%) | 436 (44.2%) | 0.138 | 83 (39.3%) | 168 (44.3%) | 0.240 |
Total cholesterol ≥ 240 (mg/dL) | 6 (2.4%) | 30 (2.8%) | 0.733 | 6 (2.5%) | 8 (2.0%) | 0.666 |
LDL cholesterol ≥ 100 (mg/dL) | 39 (15.9%) | 323 (30.7%) | <0.001 | 39 (16.3%) | 76 (19.0%) | 0.401 |
Use of statin | 51 (20.8%) | 214 (20.3%) | 0.858 | 48 (20.1%) | 90 (22.4%) | 0.482 |
Biopsy-proven acute rejection within 1 year | 64 (26.1%) | 130 (12.3%) | <0.001 | 62 (25.9%) | 41 (10.2%) | <0.001 |
eGFRa at 1 month (mL/min) | 66.4 ± 24.6 | 62.9 ± 21.3 | 0.042 | 65.7 ± 24.3 | 65.1 ± 20.6 | 0.715 |
